Philip S. Low
Next Generation Targeted Therapeutics
Lab Members
Philip Low
Dr. Philip S. Low is the Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry. Dr. Low has spent over 45 years exploring:
- targeted therapeutic and imaging agents for multiple human diseases (including several cancers, autoimmune, infectious, and inflammatory diseases),
- the structure, function, and pathologies of the erythrocyte membrane, and
- signal transduction across plant cell membranes.
He has published over 470 scientific articles and has over 360 US patents/patents pending. Eight drugs stemming from his research are undergoing human clinical trials and five companies (Endocyte Inc., OnTarget Laboratories Inc., HuLow LLC, Novosteo Inc., and ErythroCure Inc.) have been founded to commercialize these discoveries. Dr. Low received his B.S. in Chemistry from BYU (1971) and his Ph.D. in Biochemistry from UCSD (1975).
Email: plow@purdue.edu
Staff
|
Patti Cauble Administrative assistant |
Madduri Srinivasarao Lab manager |
Group Members
|
Ananada Kanduluru Visiting Scholar |
Ramesh Mukkamala Postdoc Design and development of Fibroblast Activation Protein (FAP) targeted ligands and their applications for delivery of attached imaging and therapeutic agents to cancers and fibrotic diseases. |
John Victor Napoleon Postdoc |
|
Sudarsan Reddy Kasireddy Postdoc Design and synthesis of ligand-targeted microRNAs for the selective modulation of gene expression in cancer cells in vivo |
Yashapal Singh Postdoc |
Vijai Tangadanchu Postdoc |
|
Xiaofei Yang Postdoc |
Suresh Yarlagadda Postdoc |
Fenghua Zhang Postdoc Design and preclinical testing of targeted immunotherapies for fibrotic diseases that act by selectively reprogramming profibrotic M2-like macrophages to antifibrotic M1-like macrophages. |
|
Suilan Zheng Postdoc Design of novel CAR T cell (Chimeric Antigen Receptor T cell) based immunotherapies for solid tumors that can be sensitively and continuously regulated following their infusion into cancer patients. |
Rami Alfar Ph.D. graduate student |
Spencer Gardeen Ph.D. graduate student |
|
John Hausman Ph.D. graduate student |
Bo Huang Ph.D. graduate student |
Chris Jensen Ph.D. graduate student Development of applications for steroids targeted to activated macrophages in the treatment of autoimmune and inflammatory diseases. |
|
Da Sol Jung Ph.D. graduate student Development of targeted chemo- and radiotherapeutic agents that accumulate specifically in bone metastases and eradicate the painful lesions without causing damage to healthy tissues |
Weichuan Luo Ph.D. graduate student |
Panae Noomuna Ph.D. graduate student |
|
Imrul Shahriar Ph.D. graduate student Development of bispecific small molecules that can form a bridge between a virus-infected cell and an immune effector cell leading to eradication of the viral infection. I am keenly interested in applying the principles of molecular modelling, virology and immunology to curing life-threatening viral infections. |
|
|
